The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10917 malaria professionals are enjoying the free benefits of MalariaWorld today

p. vivax

NOT Open Access | Progress towards the development of a P. vivax vaccine

January 27, 2021 - 11:18 -- NOT Open Access
Author(s): 
De SL, Ntumngia FB, Nicholas J, Adams JH
Reference: 
Expert Rev Vaccines. 2021 Jan 22

Plasmodium vivax causes significant public health problems in endemic regions. A vaccine to prevent disease is critical, considering the rapid spread of drug-resistant parasite strains, and the development of hypnozoites in the liver with potential for relapse. A minimally effective vaccine should prevent disease and transmission while an ideal vaccine provides sterile immunity. Areas covered: Despite decades of research, the complex life cycle, technical challenges and a lack of funding have hampered progress of P. vivax vaccine development.

Diagnostic Practices and Treatment for P. vivax in the InterEthnic Therapeutic Encounter of South-Central Vietnam: A Mixed-Methods Study

January 6, 2021 - 13:13 -- Open Access
Author(s): 
Nguyen TT, Nguyen XX, Gryseels C, et al.
Reference: 
Pathogens. 2020 Dec 31;10(1):E26

Malaria elimination in the Greater Mekong Sub-Region is challenged by a rising proportion of malaria attributable to P. vivax. Primaquine (PQ) is effective in eliminating the parasite's dormant liver stages and can prevent relapsing infections, but it induces severe haemolysis in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, highlighting the importance of testing enzyme activity prior to treatment.

NOT Open Access | Computational chemogenomics drug repositioning strategy enables the discovery of Epirubicin as a new repurposed hit for P. falciparum and P. vivax

June 30, 2020 - 14:57 -- NOT Open Access
Author(s): 
Ferreira LT, Rodrigues J, Costa FTM, et al.
Reference: 
Antimicrob Agents Chemother. 2020 Jun 29:AAC.02041-19

Widespread resistance against antimalarial drugs thwarts current efforts for controlling the disease and urges the discovery of new effective treatments. Drug repositioning is increasingly becoming an attractive strategy since it can reduce costs, risks and time-to-market. Herein we have used this strategy to identify novel antimalarial hits. We performed a comparative in silico chemogenomics approach to select Plasmodium falciparum and P. vivax proteins as potential drug targets and analyzed these using a computer-assisted drug repositioning pipeline to identify approved drugs with potential antimalarial activity. Among seven drugs identified as promising antimalarial candidates, the anthracycline epirubicin was selected for further experimental validation.

Comprehensive proteomics investigation of P. vivax-infected human plasma and parasite isolates

March 9, 2020 - 14:20 -- Open Access
Author(s): 
Venkatesh A, Aggarwal S, Kumar S, Rajyaguru S, Kumar V, Bankar S, Shastri J, Patankar S, Srivastava S
Reference: 
BMC Infect Dis. 2020 Mar 2;20(1):188

In recent times, Plasmodium vivax (P. vivax) has become a serious threat to public health due to its ability to cause severe infection with fatal outcomes. Its unique biology makes it resilient to control measures that are otherwise effective against P. falciparum. A deeper understanding of P. vivax biology and pathogenesis is, therefore, essential for developing the right control strategies. 

Humoral immunity prevents clinical malaria during Plasmodium relapses without eliminating gametocytes

October 1, 2019 - 14:29 -- Open Access
Author(s): 
Chester J. Joyner, Cristiana F. A. Brito, Mary R. Galinski, et al.
Reference: 
PLoS Pathog 15(9): e1007974

Plasmodium relapses are attributed to the activation of dormant liver-stage parasites and are responsible for a significant number of recurring malaria blood-stage infections.

Medical Condition: 

Phosphoethanolamine-N-methyltransferase is a potential biomarker for the diagnosis of P. knowlesi and P. falciparum malaria

March 20, 2018 - 14:28 -- Open Access
Author(s): 
Robert G. E. Krause, J. P. Dean Goldring
Reference: 
PLoS ONE 13(3): e0193833

PMT, like the pan-specific LDH biomarker used in RDT tests, is both soluble, present at comparable concentrations in the parasite and constitutes a promising antimalarial drug target.

Medical Condition: 
Medical Treatment: 

Absence of Plasmodium inui and Plasmodium cynomolgi, but detection of Plasmodium knowlesi and Plasmodium vivax infections in asymptomatic humans in the Betong division of Sarawak, Malaysian Borneo

October 18, 2017 - 12:02 -- Open Access
Author(s): 
Angela Siner, Sze-Tze Liew, Khamisah Abdul Kadir, Dayang Shuaisah Awang Mohamad, Felicia Kavita Thomas, Mohammad Zulkarnaen and Balbir Singh
Reference: 
Malaria Journal 2017 16:417, 17 October 2017

Asymptomatic human P. knowlesi and P. vivax malaria infections, but not P. cynomolgi and P. inui infections, are occurring within communities affected with malaria.

Severe Plasmodium falciparum and Plasmodium vivax malaria among adults at Kassala Hospital, eastern Sudan

May 7, 2013 - 07:56 -- Open Access
Author(s): 
Abdallah TM, Abdeen MT, Ahmed IS, Hamdan HZ, Magzoub M, Adam I
Reference: 
Malaria Journal 2013, 12:148 (1 May 2013)
MalariaWorld

Severe malaria due to P. falciparum and P. vivax malaria is an existing entity among adults in eastern Sudan. Patients with severe P. falciparum and P. vivax develop similar disease manifestations.

Country: 

IL1B, IL4R, IL12RB1 and TNF gene polymorphisms are associated with plasmodium vivax malaria in Brazil

December 10, 2012 - 08:50 -- Open Access
Author(s): 
Sortica VA, Cunha MG, Ohnishi MD, Souza JM, Ribeiro-dos-Santos ÂK, Santos NP, Callegari-Jacques SM, Santos SE, Hutz MH
Reference: 
Malaria Journal 2012, 11:409 (7 December 2012)
MalariaWorld

Plasmodium vivax malaria pathophysiology is still poorly understood.

Country: 

Plasmodium vivax malaria in Mali: a study from three different regions

December 6, 2012 - 09:01 -- Open Access
Author(s): 
Bernabeu M, Gomez-Perez GP, Sissoko S, Niambélé MB, Haibala AA, Sanz A, Théra MA, Fernandez-Becerra C, Traoré K, Alonso PL, Bassat Q, Portillo HA, Doumbo O
Reference: 
Malaria Journal 2012, 11:405 (5 December 2012)
MalariaWorld

The diagnostics of this human malaria parasite should be taken into account in the context of malaria control and elimination efforts, not only in Mali, but also in sub-Saharan Africa.

Country: 

Pages

Subscribe to RSS - p. vivax